Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment of a liver disease - primary biliary cholangitis (PBC).from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3mZyLot
via IFTTT
0 comments:
Post a Comment